MedTrace Logo

Performance of REMS Bone Densitometry in a British Population

NCT06151353 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 2500

Last updated 2025-08-17

No results posted yet for this study

Summary

Radiofrequency echographic multispectrometry (REMS) is a recently developed technology that uses ultrasound to assess bone density and bone quality. It was launched in 2018 since when OsteoscanUK Ltd has offered a clinical bone health service using a REMS scanner. REMS is an alternative to x-ray based dual energy x-ray absorptiometry (DEXA) scans which are considered the "Gold Standard" for clinical densitometry. REMS is unique in offering not only bone density but also bone quality assessments in real time for both the spine and hip.

Conditions

  • Bone Densitometry

Interventions

DIAGNOSTIC_TEST

REMS

Bone health assessment using REMS, an ultrasound technology developed to measure bone mineral density and bone toughness without ionising radiation

Sponsors & Collaborators

  • OsteoscanUK Ltd

    lead INDUSTRY

Principal Investigators

  • Nick Birch, FRCS (Orth) · Director of OsteoscanUK

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-21
Primary Completion
2030-11-20
Completion
2031-05-20
FDA Device
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06151353 on ClinicalTrials.gov